Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Mapp Biopharmaceutical / Merck & Co.

Mapp Biopharmaceutical & Merck & Co.

1 shared events · Importance 4 · Last updated May 30, 2026

Importance
4
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
27
Accidents
Unknown Event
Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how Mapp Biopharmaceutical and Merck & Co. interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.